Browse > Article
http://dx.doi.org/10.7314/APJCP.2013.14.5.2819

Effects of Femara and Tamoxifen on Proliferation of FM3A Cells in Culture  

Topcul, Mehmet (Department of Biology, Faculty of Science, Istanbul University)
Topcul, Funda (Republic of Turkey Ministry of National Education IDMIB Leather Vocational High School)
Cetin, Idil (Department of Radiobiology, Institute of Science, Istanbul University)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.14, no.5, 2013 , pp. 2819-2822 More about this Journal
Abstract
In this study, antiproliferative effects of the selective estrogen receptor modulator Tamoxifen and the aromatase inhibitor letrozole (Femara) were evaluated and compared using the FM3A cell line, originating from a C3H mouse mammary carcinoma and positive in terms of estrogen receptor (ER) expression. Cell kinetic parameters including labelling index, mitotic index and labelling index were assessed after exposure of the. FM3A cell line to $0.001{\mu}g/ml$ of Tamoxifen and $0.25{\mu}g/ml$ of Femara for 4, 8, 16 and 32 h for all parameters. The results showed that cell growth was inhibited by both agents. There was a significant decrease in labelling index and mitotic index and significant increase in apoptotic index for all experimental groups. The differences between control and all experimental groups were statistically significant (p<0.001) for all applications.
Keywords
FM3A; Tamoxifen; femara; mitotic index; labelling index; apoptotic index;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Asselin-Labat M-L, Vaillant F, Sheridan JM, et al (2010). Control of mammary stem cell function by steroid hormone signalling. Nature, 465, 798-802.   DOI   ScienceOn
2 Azria D, Larbouret C, Cunat S, et al (2005). Letrozole sensitizes breast cancer cells to ionizing radiation. Breast Cancer Res, 7, 156-63.   DOI   ScienceOn
3 Bai Z, Gus R (2009). Breast cancer, estrogen receptor and ligands. Arch Pharm Chem Life Sci, 342, 133-49.   DOI   ScienceOn
4 Baum M (1999). Use of aromatase inhibitors in the adjuvant treatment of breast cancer. Endocrine-Related Cancer, 6, 231-4.   DOI   ScienceOn
5 Baum M, Buzdar AU, Cuzick J, et al (2002). Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomized trial. Lancet, 359, 2131-9.   DOI   ScienceOn
6 Bedi KS, Goldstein DJ (1976). apparent anomalies in nuclear feulgen-DNA contents. J Cell Bio, 71, 68-88.   DOI   ScienceOn
7 Buzdar AU (2003). Advances in endocrine treatments for postmenopeusal women with metastatic and early breast cancer. Oncologist, 8, 335-41.   DOI   ScienceOn
8 Campos SM (2004). Aromatase inhibitors for breast cancer in postmenopausal women. The Oncologist, 9, 126-36.   DOI   ScienceOn
9 Cetin I, Topcul M (2012). Cancer stem cells in oncology. J BUON, 17, 644-8.
10 Davies C, Godwin J, Gray R, et al (2011). Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet, 378, 771-84.   DOI   ScienceOn
11 Dowsett M, Smith IE, Ebbs SR, et al (2005). Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival. Clin Cancer Res, 11, 951-8.
12 Gruvberger S, Ringner M, Chen Y, et al (2001). Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. Cancer Res, 61, 5979-84.
13 Jordan VC (2003). Tamoxifen: a most unlikely pioneering medicine. Nat Rev Drug Discov, 2, 205-13.   DOI   ScienceOn
14 Kjellstrand P (1980). Mechanisms of the feulgen acid hydrolysis. J Microscopy, 119, 391-6.   DOI   ScienceOn
15 Klotz IM (1982). Numbers of receptor sites from Scatchard graphs: facts and fantasies. Science, 217, 1247-9.   DOI
16 Long BJ, Jelovac D, Handratta V, et al (2004). Therapeutic strategies using the aromatase inhibitor letrozole and tamoxifen in a breast cancer model. J National Cancer Institute, 96, 456-65.   DOI   ScienceOn
17 McGuire WL, Tandon AK, Allred DC, Chamness GC, McClark GM (1990). How to use prognostic factors in axillary node-negative breast cancer patients. J Natl Cancer Inst, 82, 1006-15.   DOI
18 Mouridsen H, Gershanovich M, Sun Y, et al (2003). Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the international letrozole breast cancer group. J Clin Oncol, 21, 2101-9.   DOI   ScienceOn
19 O'Neill M, Paulin FEM, Vendrell J, Ali CW, Thompson AM (2012). The aromatase inhibitor letrozole enhances the effect of doxorubicin and docetaxel in an MCF7 cell line model. BioDiscovery, 6, 1-8.
20 Mouridsen HT (2007). Letrozole in advanced breast cancer: the PO25 trial. Breast Cancer Res Treat, 105, 19-29.   DOI
21 Osborne CK (1998). Tamoxifen in the treatment of breast cancer. N Engl J Med, 339, 1609.   DOI   ScienceOn
22 Ponzone R, Mininanni P, Cassina E, Pastorino F, Sismondi P (2008). Aromatase inhibitors for breast cancer: different structures, same effects? Endocr Relat Cancer, 15, 27-36.   DOI   ScienceOn
23 Santen RJ, Harvey HA (1999). Use of aromatase inhibitors in breast carcinoma. Endocrine-Related Cancers, 6, 75-92.   DOI   ScienceOn